Just Released - Transplantation Direct - March 2023 Issue
The March issue of Transplantation Direct is online and open for everyone. Several articles on immunosuppression in kidney transplantation offer insight on long-term outcomes using prolonged-release tacrolimus, Belatacept dosing every 2 months vs 1 month (an RCT), immunosuppression adherence in Japan, and fasting status and circadian variation with MMF and the glucoronate metabolite. Additionally, there is a report on first-in-human use of a novel thermal barrier bag during kidney transplantation. On the topic of liver transplantation, we have articles on the use of an anticoagulation stratification algorithm and on the role of pretransplant infections in pediatric LDLT recipients. For the cardiologists, a study looks at the influence of tricuspid regurgitation after heart transplantation and another tests ex vivo heart perfusion in the US to push the distance to transplant center boundaries. This issue also features articles on organ donation and procurement, including a first trial of special flushing procedures to reduce bile duct injury, a study estimating acquired blood borne virus infections in donated organs (Australia), utilization and outcomes from normothermic regional perfusion programs using DCD organs, and the role of center-specific factors play into use of COVID+ organs. Also related to the recent COVID outbreak, spread of community-acquired respiratory infections in lung transplant recipients is examined. Not to be left out, an article on busulfan or treosulfan conditioning in older patients is available for our hematopoietic stem cell transplant experts. Many facet of transplantation medicine are covered in this Transplantation Direct issue – please visit our open access site for further details.
The Molecular Microscope Diagnostic System (MMDx) may overcome histology shortcomings. Previous studies have simply examined discrepant findings but have not attempted to determine clinical endpoints. To measure performance, clinical outcomes are strongly required.
Solid organ transplantation is the therapy of choice for many patients with end-stage organ failure; however, recipients must remain on lifelong immunosuppression, leaving them susceptible to infections and cancer. The study of transplant tolerance to prolong graft survival in the absence of immunosuppression has been restricted to recipients of living donor allografts; however, deceased donors significantly outnumber living donors. Mobilization of hematopoietic stem cells (HSCs) from the bone marrow to peripheral blood (PB) could allow PB-HSCs to be used to induce tolerance in deceased donor kidney recipients; however, a major concern is the well-known concomitant mobilization of immune cells into the liver.
The THEORY study evaluated the effects of single and multiple doses of obinutuzumab, a type 2 anti-CD20 antibody that induces antibody-dependent cell-mediated cytotoxicity and direct cell death, in combination with standard of care in patients with end-stage renal disease.
Long-term outcome data by induction type in simultaneous pancreas-kidney (SPK) is limited. Utilizing the Scientific Registry of Transplant Recipients, we examined all primary SPK transplants between 2000 and 2020, excluding crossmatch-positive recipients.
Report from Baskent Unversity following the devastating earthquake that hit Turkey and Syria
We have set up a donation page for victims of the earthquake - click for details
Following the devastating earthquake that hit Turkey and Syria on Monday, February 6, 2023, more than 34000 people have lost their lives and tens of thousands have been injured. Relief efforts are ongoing one week after the quake struck and aid campaigns are being organized from all over Turkey and the world.
On Tuesday May 2nd at 17:00-18:00 local time (Eastern Time), all are invited to a special networking event where Dr. Jayne Danska (The Hospital for Sick Children, Toronto, Canada) and Professor Lorna Marson (University of Edinburgh, United Kingdom) will talk about overcoming barriers to career advancement as a woman in the field of transplantation. A discussion will follow. There is no separate registration fee for this event for all who are registered for the ITS meeting, and all are welcome.
On the following morning, Dr. Danska will represent WIT during a session on Influence of Sex and Gender in Transplantation with a talk on "Interactions between Sex and Microbiome Responses", on Wednesday May 3rd at 08:00-09:20 local time.
Upcoming Meeting Announcements
Early Bird Registration Deadline: March 8th
Don't miss joining us in Cambridge, MA from April 24-25, 2023 for the 4th IPITA/HSCI/JDRF Summit on Stem Cell Derived Beta Cells!
The workshop program offers world-renowned expert speakers presenting highly innovative science with state-of-the-art developments. Workshop topics will include:
Identifying persistent challenges still such as developing beta cells with full physiologic function
Understanding the potential role of genome engineering to modify cells for therapeutic advantage
Identifying optimal transplant platforms and encapsulation technologies
Developing effective approaches to escape allo-, and autoimmunity
Update on competing technologies including blastocyst complementation and gene edited xenografts
Presenting recent preclinical and clinical trial results.
We look forward to your participation!
Detailed Program is Now Available!
It is not too late to register and book your hotel!